Centrose Announces Issuance of the First EDC Patent
Centrose announces the issuance of the first patent that covers a new class of antibody drug conjugates. The patent covers a new cancer drug candidate for treating metastatic drug resistant cancers.
Madison, Wisconsin (PRWEB) June 25, 2013
Centrose, a company focused on developing safer and more effective therapies that improve patient health, announced today that the United States Patent and Trademark Office (USPTO) issued Centrose its first Extracellular Drug Conjugate (EDC) Patent. U.S. Patent number 8,470,980 relates to the first EDC ever discovered. EDC1 is one of a family of Class I EDCs from Centrose that target hard to treat metastatic and drug resistant cancers.
Exclusive to Centrose, this invention is specific to a “first in class” drug candidate called EDC1 which kills cancers at their deadliest phase. For tumors to become metastatic, new proteins are made on their cell surfaces and form multi-protein complexes. These multi-protein complexes allow cancer cells to become drug resistant and mobile. This in turn makes these later stage cancers extremely life threatening.
EDC1 targets complexed surface proteins made by late stage cancers. First, EDC1 uses a drug which is part of a class of drugs that occur naturally in the human body to regulate cell growth. Second, EDC1 uses antibodies (another class of molecules naturally produced in humans), to guide the drug specifically to later stage cancers. EDC1’s antibody binds dysadherin, a protein found to be an important marker for late stage cancers. Because the targets of the drug and antibody form a complex, EDC1 brings the drug right to its target, killing the cancer. Initial toxicology data on this next generation antibody drug conjugate predicts that EDC1 will be safe to patients, and preclinical testing using cancers directly from patients show EDC1 to be extremely effective at killing multidrug resistant tumor cells.
“EDC1 deserves significant attention as it is a completely novel approach and backed up by solid science,” stated Dr. James Prudent. “This patent secures value to those who have invested in both Centrose and in the fight against cancer.”
Centrose is waging war against diseases using a new understanding of cell surface biochemistry. Using this information, Centrose is now finding unconventional ways to specifically redirect crucial cancer causing pathways. Centrose intends to make significant progress at fighting disease and strives to do this in the shortest amount of time. Better life through better science, that’s Centrose.
For the original version on PRWeb visit: http://www.prweb.com/releases/2013/6/prweb10855172.htm